ArticleScientific reports2026
Integrated UPLC, bioinformatics, and in vitro analyses reveal Yiqihuoxue decoction (GSC) alleviates vascular aging by promoting autophagy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Vascular aging constitutes a predominant risk factor for cardiovascular pathologies. Traditional Chinese Medicine (TCM) employs various formulations to mitigate age-related vascular dysfunction, among which Yiqihuoxue decoction (GSC) is clinically utilized for managing cardiovascular conditions in elderly patients. Our prior work demonstrated GSC’ s capacity to delay vascular aging in mice models and attenuate senescence in vascular endothelial cells, though its mechanistic basis remained unresolved. To address this, we conducted multi investigation combining Ultra-Performance Liquid Chromatography (UPLC), network pharmacology, and molecular dynamics (MD) simulations. UPLC identified 130 bioactive compounds in GSC, while integrative analyses (mass spectrometry, literature mining, and target prediction) revealed 792 putative targets. Intersection with 2,539 vascular aging-associated targets yielded 422 shared candidates, suggesting GSC’ s polypharmacological potential. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses highlighted autophagy-related pathways, notably PI3K/Akt and SIRT1 signaling. Cellular validation experiments in senescent human umbilical vein endothelial cells (HUVECs) demonstrated that GSC restored cell morphology and reduced SA-β-gal activity (p < 0.05). GSC alleviated G0/G1 phase cell cycle arrest, restored mitochondrial membrane potential, and suppressed ROS accumulation. Autophagy profiling indicated that GSC promoted autophagic flux, as evidenced by increased LC3B puncta formation in immunofluorescence assays and autophagosome accumulation observed via transmission electron microscopy. Mechanistically, GSC exerted anti-senescence effects via coordinated regulation of the SIRT1-autophagy axis and PI3K/AKT pathway inhibition. Western blotting confirmed dose-dependent upregulation of SIRT1 and downregulation of p-PI3K/p-AKT (p < 0.05), consistent with network pharmacology predictions. This study established GSC as a multi-component, multi-target intervention against vascular aging, with autophagy modulation serving as a central mechanism. These findings will provide a theoretical foundation for developing GSC-based therapies targeting age-related cardiovascular diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.